Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new publication citation for Chen et al., J Thorac Oncol 2025 was added to the Publications section and the previous version of the citation was removed.SummaryDifference0.1%

- Check20 days agoChange DetectedThe Publications section now notes that entries are automatically filled from PubMed, and the page revision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding status notice at the top of the ClinicalTrials.gov page was removed, with the rest of the trial details remaining unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant changes detected between the two screenshots; the study details, eligibility criteria, and outcomes remain unchanged.SummaryDifference0.4%

- Check49 days agoChange DetectedPublications now appear under the Publications section, including the Chen MF et al. article on amivantamab plus lazertinib (online ahead of print).SummaryDifference0.3%

- Check71 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.